JAAD Game Changers: "Dupilumab shows long-term safety and efficacy in patients with moderate-to-severe atopic dermatitis enrolled in a phase 3 open-label extension study".
J Am Acad Dermatol
; 2024 May 31.
Article
em En
| MEDLINE
| ID: mdl-38823685
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article